Weekly Recap | Novanta -8.84%, consensus target above spot
I'm LongbridgeAI, I can summarize articles.Novanta (NOVT) fell 8.84% this week to close at $128.79, trailing the S&P 500 by about 6.89 percentage points, with the benchmark down 1.95%. The week opened strong on Monday (Oct 12), when the stock climbed to $145.03, and Tuesday saw an intraday high of $148.60 before momentum faded. From Wednesday through Friday the stock lost ground, ending the week at $128.79 after touching $128.57 on Oct 16, the lowest level in a 60-session window.
The Week
Novanta (NOVT) fell 8.84% this week to close at $128.79, trailing the S&P 500 by about 6.89 percentage points, with the benchmark down 1.95%. The week opened strong on Monday (Oct 12), when the stock climbed to $145.03, and Tuesday saw an intraday high of $148.60 before momentum faded. From Wednesday through Friday the stock lost ground, ending the week at $128.79 after touching $128.57 on Oct 16, the lowest level in a 60-session window.
Key Events
Novanta announced the schedule for its third quarter 2026 earnings release and conference call on Oct 13, shifting attention to the upcoming results. The same day, sector news on GLP-1 pricing shifts and lithium deals added to a cautious tone. On Oct 16, an analysis suggested Novanta could be 31% below fair value on its medical growth story, bringing the valuation debate back into focus. Together, the week’s news points to a stock waiting for its own catalyst while trading against a nervous tape.
Analyst Ratings
Three brokers cover Novanta: two rate it buy and one rates it overweight, giving a consensus rating of strong buy. The consensus target price is $194.50, about 51.02% above the latest close, with target prices clustered narrowly between $194 and $195. Novanta ranks 36th out of 67 companies in the electronic equipment and services industry.
The Week Ahead
Next week’s macro calendar leans towards housing: the NAHB housing market index on Oct 19, followed by housing starts and building permits on Oct 20, could sway rate expectations and sentiment around tech and medical-device names. Novanta’s third-quarter report is set for Nov 9 after the close, with estimates at $0.515 EPS and about $301m in revenue, but that is beyond the immediate window. The nearer question is whether the stock can hold above $128.57, the recent range low.
In Short
This week carries a tension between bullish ratings and a falling price. The consensus rating remains strong buy with a target about 51% above spot, yet the stock closed at a 60-day low, and the latest session showed net selling from large-lot money against net buying from smaller accounts. The next test is whether upcoming earnings can validate the medical growth narrative and whether $128.57 becomes support.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.